CTVA vs SPRO · P/E 42, rev $16.91B vs P/E 9.6, rev $48.0M
Corteva Inc (CTVA) versus Spero Therapeutics Inc (SPRO) — a side-by-side from cached financials, not a winner call.
Corteva Inc (CTVA) is a agricultural inputs company listed on US.
Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.
Latest reported CTVA revenue for 2024-12-31 was $16.91B. Net income was $919.0M. Revenue was down 1.8% from 2023-12-31 to 2024-12-31. CTVA currently screens at market cap $51.52B and trailing P/E 41.6.
Latest reported SPRO revenue for 2024-12-31 was $48.0M. Net income was -$68.6M. Revenue was down 53.8% from 2023-12-31 to 2024-12-31. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
CTVA currently screens at market cap $51.52B and trailing P/E 41.6. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
Not investment advice. Open the CTVA and SPRO stock pages for the full models.
Not investment advice.